Cullinan Therapeutics

#ICYMI: In a recent article with Springer Nature, we explore our efforts to address the need for therapies providing durable remission in #autoimmune diseases. ? ? Read the full article to learn more about our research into the potential of T cell engagers targeting CD19 to go beyond symptom control: https://bit.ly/48DPw16?

The lung cancer community urgently needs the #biotech industry to adopt innovative strategies that push the boundaries of scientific progress. In a blog post?with MassBio, Jeff Jones, MD, MBA, Chief Medical Officer, discusses the importance of leaning into a “clinician’s mindset” and embracing collaboration?to deliver new standards of care for people living with lung cancer and their families. Read the full article: https://bit.ly/40XgxuK #LungCancerAwarenessMonth #LCAM?

Today at 1:50 p.m. ET, Nadim Ahmed, President and CEO, and Jeff Jones, MD, MBA, Chief Medical Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference in New York, NY. A live webcast and recording will be available here: https://bit.ly/4bD5WHU

Join us in congratulating Rose Weldon, Senior Vice President, Corporate Affairs, for her recognition as a Life Sciences Voice Rising Star Award recipient. The award recognizes the rising stars in the life sciences industry who are bringing positive change and enabling transformation in the sector. Rose consistently demonstrates her commitment to the industry and to Cullinan through strong leadership, an unmatched ability to innovate when challenges arise, and so much more. Congratulations on this well-deserved recognition, Rose! #LifeSciencesVoice #RisingStar

Last night, #LupusTherapeutics, clinical affiliate of the #Lupus Research Alliance, hosted an educational session on T cell engagers, sponsored by Cullinan Therapeutics. The discussion, moderated by Stacie Bell, PhD, Executive Vice President of #LupusTherapeutics, featured expert perspectives from Jeff Jones, MD, MBA, Chief Medical Officer at Cullinan Therapeutics and Anca Askanase, MD, MPH, Founder and Clinical Director of Columbia University Lupus Center; Director, Rheumatology Clinical Trials. A special thanks to Cullinan Therapeutics and the panelists for an insightful discussion and for your continued commitment in advancing #lupusclinicalresearch! ??

The immune system is a complex defense network that continuously seeks balance to keep our bodies healthy. An overly active immune response, mainly driven by dysregulated B cells and/or T cells,?is thought to cause many #autoimmune diseases. CD19-directed T cell engagers are a promising modality for depleting B cells, with disease-modifying potential for patients with certain autoimmune diseases.? ? Learn more about our investigation into targeting CD19 with T cell engagers for autoimmune diseases: https://bit.ly/3CclIMY #ACR24

Don’t miss us at #ACR24! Stop by our booth (#2304) to meet our team and learn more about our work in #autoimmune diseases. ? ? Tomorrow, we’ll be presenting preclinical data evaluating CLN-978, our CD19xCD3 bispecific T cell engager, and its potential as a treatment for autoimmune diseases like systemic lupus erythematosus (#SLE). ? ? Get more details on our presentation here: https://bit.ly/3OavTEw

Despite advances in #autoimmune disease research, there remains an unmet need for treatments that provide durable remission for patients. Learn more about our investigation into CD19-directed T cell engagers in an effort to create new standards of care for patients with autoimmune diseases like systemic lupus erythematosus (#SLE).? ? Visit our booth (#2304) at #ACR24 or view our fact sheet to learn more about our research: https://bit.ly/3NYguHj

Today, we shared preclinical data evaluating CLN-978, our CD19xCD3 bispecific T cell engager. These data will be presented at #ACR24 on Saturday, November 16, between 10:30 a.m. and 12:30 p.m. ET. Learn more: https://bit.ly/4fxb5mL

#Autoimmune disease drug development is seeing renewed innovation and interest, paving the way for more flexible, patient-friendly therapies. Emerging options like T cell engagers show potential as off-the-shelf treatments. In this article with BioPharma Dive, industry experts including our Chief Medical Officer Jeff Jones, MD, MBA, explore how a modality-agnostic approach and innovation-without-borders philosophy better enables the rapid, strategic advancement of potential new standards of care for patients. Read the full article: https://bit.ly/4fGuVvz